Literature DB >> 35386946

Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.

Cosimo Bruni1, Maya H Buch2,3, Daniel E Furst1,4, Giacomo De Luca5, Aleksandra Djokovic6,7, Raluca B Dumitru8, Alessandro Giollo9, Marija Polovina6, Alexia Steelandt10, Kostantinos Bratis11, Yossra Atef Suliman12, Ivan Milinkovic6, Anna Baritussio13, Ghadeer Hasan14, Anastasia Xintarakou15, Yohei Isomura16, George Markousis-Mavrogenis17, Lorenzo Tofani1, Sophie Mavrogeni17, Luna Gargani18, Alida Lp Caforio13,19, Carsten Tschöpe20, Arsen Ristic6, Karin Klingel21, Sven Plein22, Elijah R Behr23,24, Yannick Allanore9, Masataka Kuwana16, Christopher P Denton25, Dinesh Khanna26, Thomas Krieg27, Renzo Marcolongo13,28, Ilaria Galetti29, Elisabetta Zanatta30, Francesco Tona31, Petar Seferovic6,7,32, Marco Matucci-Cerinic1,5,33.   

Abstract

Introduction: Primary heart involvement in systemic sclerosis may cause morpho-functional and electrical cardiac abnormalities and is a common cause of death. The absence of a clear definition of primary heart involvement in systemic sclerosis limits our understanding and ability to focus on clinical research. We aimed to create an expert consensus definition for primary heart involvement in systemic sclerosis.
Methods: A systematic literature review of cardiac involvement and manifestations in systemic sclerosis was conducted to inform an international and multi-disciplinary task force. In addition, the nominal group technique was used to derive a definition that was then subject to voting. A total of 16 clinical cases were evaluated to test face validity, feasibility, reliability and criterion validity of the newly created definition.
Results: In total, 171 publications met eligibility criteria. Using the nominal group technique, experts added their opinion, provided statements to consider and ranked them to create the consensus definition, which received 100% agreement on face validity. A median 60(5-300) seconds was taken for the feasibility on a single case. Inter-rater agreement was moderate (mKappa (95% CI) = 0.56 (0.46-1.00) for the first round and 0.55 (0.44-1.00) for the second round) and intra-rater agreement was good (mKappa (95% CI) = 0.77 (0.47-1.00)). Criterion validity showed a 78 (73-84)% correctness versus gold standard.
Conclusion: A preliminary primary heart involvement in systemic sclerosis consensus-based definition was created and partially validated, for use in future clinical research.
© The Author(s) 2021.

Entities:  

Keywords:  Systemic sclerosis; cardiac involvement; definition; heart

Year:  2021        PMID: 35386946      PMCID: PMC8922675          DOI: 10.1177/23971983211053246

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  34 in total

1.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

2.  The mighty fibroblast and its utility in scleroderma research.

Authors:  Sara M Garrett; DeAnna Baker Frost; Carol Feghali-Bostwick
Journal:  J Scleroderma Relat Disord       Date:  2017-05-19

3.  Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient.

Authors:  C Bruni; S Bellando-Randone; L Gargani; E Picano; A Pingitore; M Matucci-Cerinic; S Guiducci
Journal:  Reumatismo       Date:  2016-09-09

4.  A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study.

Authors:  Muriel Elhai; Jérôme Avouac; Ulrich A Walker; Marco Matucci-Cerinic; Gabriela Riemekasten; Paolo Airò; Eric Hachulla; Gabriele Valentini; Patricia E Carreira; Franco Cozzi; Alexandra Balbir Gurman; Yolanda Braun-Moscovici; Nemanja Damjanov; Lidia P Ananieva; Raffaella Scorza; Sergio Jimenez; Joanna Busquets; Mengtao Li; Ulf Müller-Ladner; André Kahan; Oliver Distler; Yannick Allanore
Journal:  Ann Rheum Dis       Date:  2014-10-23       Impact factor: 19.103

5.  Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.

Authors:  Lesley-Anne Bissell; Marina Anderson; Malcolm Burgess; Kuntal Chakravarty; Gerry Coghlan; Raluca B Dumitru; Lee Graham; Voon Ong; John D Pauling; Sven Plein; Dominik Schlosshan; Peter Woolfson; Maya H Buch
Journal:  Rheumatology (Oxford)       Date:  2017-06-01       Impact factor: 7.580

6.  Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Authors:  Maarten Boers; John R Kirwan; George Wells; Dorcas Beaton; Laure Gossec; Maria-Antonietta d'Agostino; Philip G Conaghan; Clifton O Bingham; Peter Brooks; Robert Landewé; Lyn March; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell
Journal:  J Clin Epidemiol       Date:  2014-02-28       Impact factor: 6.437

7.  Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal.

Authors:  Amelia Spinella; Francesca Coppi; Anna Vittoria Mattioli; Federica Lumetti; Rosario Rossi; Emanuele Cocchiara; Michele Colaci; Giuseppe Boriani; Clodoveo Ferri; Carlo Salvarani; Dilia Giuggioli
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2018-09       Impact factor: 2.160

8.  An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Authors:  Murray Baron; Bashar Kahaleh; Elana J Bernstein; Lorinda Chung; Philip J Clements; Christopher Denton; Robyn T Domsic; Nava Ferdowsi; Ivan Foeldvari; Tracy Frech; Jessica K Gordon; Marie Hudson; Sindhu R Johnson; Dinesh Khanna; Zsuzsannah McMahan; Peter A Merkel; Sonali Narain; Mandana Nikpour; John D Pauling; Laura Ross; Antonia Maria Valenzuela Vergara; Alessandra Vacca
Journal:  J Scleroderma Relat Disord       Date:  2018-07-18

9.  Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Authors:  Y A Suliman; C Bruni; S R Johnson; E Praino; M Alemam; N Borazan; L Cometi; B Meyers; D Khanna; Y Allanore; M Baron; T Krieg; A Herrick; A Afonso; O Distler; S Kafaja; C P Denton; M Matucci-Cerinic; D E Furst
Journal:  J Scleroderma Relat Disord       Date:  2017-05-19

10.  Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features.

Authors:  Anna-Maria Hoffmann-Vold; Oliver Distler; Baron Murray; Otylia Kowal-Bielecka; Dinesh Khanna; Yannick Allanore
Journal:  RMD Open       Date:  2019-03-04
View more
  1 in total

Review 1.  Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies.

Authors:  Arianna Ferlito; Corrado Campochiaro; Alessandro Tomelleri; Lorenzo Dagna; Giacomo De Luca
Journal:  J Scleroderma Relat Disord       Date:  2022-03-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.